key: cord-0776620-bja3yi5a authors: Schwab, Nadine A.; DesRuisseaux, Libby A.; Weinberg, Marc S.; Arnold, Steven E. title: Saving cognitive outcome data in Alzheimer's disease clinical trials during the COVID‐19 pandemic: Commentary on the virtual administration of the ADAS‐Cog date: 2020-12-16 journal: Alzheimers Dement (N Y) DOI: 10.1002/trc2.12081 sha: 581657b04556d97ca6beb356817ed9b9f3a3f3e0 doc_id: 776620 cord_uid: bja3yi5a Elderly participants in Alzheimer's disease (AD) clinical trials are at high risk of morbidity and mortality with interpersonal exposure to COVID‐19, a situation that is likely to continue for the foreseeable future. Yet, in‐person neuropsychological assessments remain the mainstay primary outcomes for clinical trials seeking prevention and cure for AD. The Alzheimer's Disease Assessment Scale‐Cognitive (ADAS‐Cog) is among the most commonly used cognitive assessment in AD clinical trials, and though currently lacking specific guidelines for virtual administrations, it can be used remotely with appropriate modifications and considerations. Here we propose a novel method of virtual administration of the ADAS‐Cog, which considers workarounds for technological and human limitations imposed when the participant is no longer sitting across from the test administrator. The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) 1,2 is the most commonly administered cognitive assessment in clinical trials of Alzheimer's disease (AD) and is frequently used as a primary outcome measure of treatment effectiveness in drug trials. 3 It consists of 11 sections and tests broad domains of cognitive functioning. The test was developed for in-person administration in a standardized office setting. However, the COVID-19 pandemic has necessitated a shift toward non-standardized methods of administration, as the inter- Other research further supports virtual testing in both cognitively healthy and impaired populations. 5 It is important to note that access to adequate technology to enable a virtual study visit may not be possible for some research participants, such as those in remote areas with limited internet access or those with lower socioeconomic status. While every effort should be made to include every individual enrolled in the trial, the issue of lack of access to technology is, for some, an unfortunate and unavoidable obstacle common to any virtual approach. SPs are provided with a copy of necessary testing stimuli (see Table 1 ) via mail ahead of the scheduled visit and are instructed not to reveal materials to the participant until the appropriate time. SPs are also asked to gather specific materials from their own items to assist with the Commands and Ideational Praxis subsections (see Table 1 ). Critically, the visit's procedures should be well planned and rehearsed by the test administration staff to ensure seamless flow of testing during the virtual visit. The test administrator should be provided the full ADAS-Cog testing kit and asked to prepare Object Naming stimuli in order of their presentation before each administration. A supervising neuropsychologist should also prepare a virtual administration script for administrators to follow during the session. See supporting information for a Manual of Procedures that includes such a script and other important elements of virtual ADAS-Cog administration. Although virtual administration of ADAS-Cog is feasible, the testing session is likely to take more time and may be more taxing on the The majority of the ADAS-Cog can be completed with only minor deviations from normal procedures and small technological adjustments. Orientation to place/location should be altered so the participant is asked to identify their location more specifically than simply "home"; they may respond with the room of the house in which the testing is taking place OR their specific home address OR the type of home (ie, single-family ranch style, specific name of condominium); see supporting information for details. Yes, without significant deviation Word cards should be in full view of the camera. Yes, without significant deviation Unaltered. Yes, without significant deviation Unaltered; instances in which comprehension was disrupted due to audio latencies should not be considered. Word-Finding Difficulty Yes, without significant deviation Unaltered. Spoken Language Ability Yes, without significant deviation Unaltered. Paucity of language should be considered in the context of the participant's comfort level with the virtual environment. Paraphasias and other nuanced language impairments may be missed due to audio disruption. SPs may be helpful in clarifying whether language abilities exhibited during the visit are typical of the participant's everyday speech. Concentration/Distractibility Yes, without significant deviation Consider the testing environment; some level of distractibility should be considered normal in situations in which disruptions in the environment are uncontrollable (i.e., traffic noise, neighborhood dogs barking). Virtual administration is not possible without major deviations in subtest instructions, subtest practice, and administration. Virtual administration is not possible without major deviations in subtest instructions, subtest practice, and administration. One major deviation, however, was our decision to omit Mazes and Number Cancellation from virtual administration because they require the presence of a testing administrator to appropriately explain instructions, and to provide both feedback and error correction during practice and completion of the subtests. Another significant alteration was made in the procedure for the Finger Naming subtest to adjust for the fact that the testing administrator would not be able to point to the participant's fingers. Instead, administrators hold up their own hand in view of the camera and ask participants to name the finger he or she is pointing to (see Table 1 ). Global circumstances demand new means of assessments in clinical trials, balancing safety with valid continuity of research. By switching from a highly controlled face-to-face assessment in AD to virtual assessment in remote settings, the field confronts uncertainties of major outcomes based on missing or noisy data. On the other hand, we may find that home assessment with steadily improving technologies will improve research participation, decrease the burden (or risk) of travel, and broaden access of older adults to the research with which we hope to cure AD. Here, we present a straightforward means of assessing cognition using a slightly modified ADAS-Cog, the current gold standard for cognitive assessment in AD clinical trials. We see this as both a functional alternative to the traditional approach, as well as a starting point for continued discussion and improvement by the broader neuropsychological and AD clinical trials community. The authors have no conflicts of interest to disclose. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy A new rating scale for Alzheimer's disease Current Alzheimer's disease clinical trials: methods and placebo outcomes Neuropsychological test administration by videoconference: a systematic review and metaanalysis Teleneuropsychology: evidence for video teleconference-based neuropsychological assessment Validity of teleneuropsychological assessment in older patients with cognitive disorders Remote neuropsychological assessment of elderly Japanese population using the Alzheimer's Disease Assessment Scale: a validation study Cognitive assessment of patients with Alzheimer's disease by telemedicine: pilot study Clinical Trial Conduct During the COVID-19 Pandemic. Emergency Preparedness Validity of teleneuropsychology for older adults in response to COVID-19: a systematic and critical review SUPPORTING INFORMATION Additional supporting information may be found online in the Supporting Information section at the end of the article. How to cite this article Alzheimer's disease clinical trials during the COVID-19 pandemic: commentary on the virtual administration of the ADAS-Cog. Alzheimer's Dement